TOP2A
Summary: This gene encodes a DNA topoisomerase, an enzyme that controls and alters the topologic states of DNA during transcription. This nuclear enzyme is involved in processes such as chromosome condensation, chromatid separation, and the relief of torsional stress that occurs during DNA transcription and replication. It catalyzes the transient breaking and rejoining of two strands of duplex DNA which allows the strands to pass through one another, thus altering the topology of DNA. Two forms of this enzyme exist as likely products of a gene duplication event. The gene encoding this form, alpha, is localized to chromosome 17 and the beta gene is localized to chromosome 3. The gene encoding this enzyme functions as the target for several anticancer agents and a variety of mutations in this gene have been associated with the development of drug resistance. Reduced activity of this enzyme may also play a role in ataxia-telangiectasia. [provided by RefSeq, Jul 2010].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| DNA topoisomerase II alpha | MIM:126430 | Ensembl:ENSG00000131747 | HGNC:HGNC:11989 | PA354 | 17q21.2 |
GO terms in TOP2A
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| BP | IBA | GO:0000712 | resolution of meiotic recombination intermediates |
| BP | IBA | GO:0000819 | sister chromatid segregation |
| BP | IEA | GO:0002244 | hematopoietic progenitor cell differentiation |
| BP | IDA | GO:0006265 | DNA topological change |
| BP | IMP | GO:0006265 | DNA topological change |
| BP | IDA | GO:0006266 | DNA ligation |
| BP | IDA | GO:0006974 | cellular response to DNA damage stimulus |
| BP | IMP | GO:0007059 | chromosome segregation |
| BP | IBA | GO:0030263 | apoptotic chromosome condensation |
| BP | IDA | GO:0030263 | apoptotic chromosome condensation |
| BP | IEA | GO:0040016 | embryonic cleavage |
| BP | ISS | GO:0042752 | regulation of circadian rhythm |
| BP | IDA | GO:0043065 | positive regulation of apoptotic process |
| BP | IBA | GO:0044774 | mitotic DNA integrity checkpoint |
| BP | IMP | GO:0045070 | positive regulation of viral genome replication |
| BP | IMP | GO:0045870 | positive regulation of single stranded viral RNA replication via double stranded DNA intermediate |
| BP | IEA | GO:0045944 | positive regulation of transcription by RNA polymerase II |
| BP | IEA | GO:0048511 | rhythmic process |
| BP | IMP | GO:1905463 | negative regulation of DNA duplex unwinding |
| CC | IDA | GO:0000228 | nuclear chromosome |
| CC | IEA | GO:0000793 | condensed chromosome |
| CC | IBA | GO:0005634 | nucleus |
| CC | IDA | GO:0005634 | nucleus |
| CC | IDA | GO:0005654 | nucleoplasm |
| CC | TAS | GO:0005654 | nucleoplasm |
| CC | IDA | GO:0005730 | nucleolus |
| CC | IDA | GO:0005730 | nucleolus |
| CC | IDA | GO:0005814 | centriole |
| CC | IDA | GO:0009330 | DNA topoisomerase complex (ATP-hydrolyzing) |
| CC | NAS | GO:0019035 | viral integration complex |
| CC | IDA | GO:0032991 | protein-containing complex |
| CC | IDA | GO:1990904 | ribonucleoprotein complex |
| MF | IDA | GO:0000287 | magnesium ion binding |
| MF | IDA | GO:0003677 | DNA binding |
| MF | IDA | GO:0003682 | chromatin binding |
| MF | HDA | GO:0003723 | RNA binding |
| MF | IDA | GO:0003918 | DNA topoisomerase type II (ATP-hydrolyzing) activity |
| MF | IMP | GO:0003918 | DNA topoisomerase type II (ATP-hydrolyzing) activity |
| MF | IPI | GO:0005080 | protein kinase C binding |
| MF | IPI | GO:0005515 | protein binding |
| MF | IEA | GO:0005524 | ATP binding |
| MF | IPI | GO:0008022 | protein C-terminus binding |
| MF | IDA | GO:0008094 | DNA-dependent ATPase activity |
| MF | IDA | GO:0008144 | drug binding |
| MF | IDA | GO:0008301 | DNA binding, bending |
| MF | IPI | GO:0019899 | enzyme binding |
| MF | IPI | GO:0042803 | protein homodimerization activity |
| MF | IPI | GO:0042826 | histone deacetylase binding |
| MF | IMP | GO:0043130 | ubiquitin binding |
| MF | IPI | GO:0046982 | protein heterodimerization activity |
Gene expression in normal tissue: TOP2A
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in TOP2A
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| wikipathways | WP1858 | Mitotic G1-G1-S phases |
| wikipathways | WP2361 | Gastric Cancer Network 1 |
| wikipathways | WP2363 | Gastric Cancer Network 2 |
| wikipathways | WP2446 | Retinoblastoma (RB) in Cancer |
| smpdb | SMP00442 | Etoposide Action Pathway |
| smpdb | SMP00443 | Teniposide Action Pathway |
| smpdb | SMP00601 | Etoposide Metabolism Pathway |
| smpdb | SMP00602 | Teniposide Metabolism Pathway |
| pharmgkb | PA165292163 | Doxorubicin Pathway (Cancer Cell), Pharmacodynamics |
| pharmgkb | PA2025 | Etoposide Pathway, Pharmacokinetics/Pharmacodynamics |
| pid | deltanp63pathway | Validated transcriptional targets of deltaNp63 isoforms |
| reactome | R-HSA-1362277 | Transcription of E2F targets under negative control by DREAM complex |
| reactome | R-HSA-1538133 | G0 and Early G1 |
| reactome | R-HSA-1640170 | Cell Cycle |
| reactome | R-HSA-2990846 | SUMOylation |
| reactome | R-HSA-2990846 | SUMOylation |
| reactome | R-HSA-3108232 | SUMO E3 ligases SUMOylate target proteins |
| reactome | R-HSA-3108232 | SUMO E3 ligases SUMOylate target proteins |
| reactome | R-HSA-392499 | Metabolism of proteins |
| reactome | R-HSA-392499 | Metabolism of proteins |
| reactome | R-HSA-453279 | Mitotic G1-G1/S phases |
| reactome | R-HSA-4615885 | SUMOylation of DNA replication proteins |
| reactome | R-HSA-4615885 | SUMOylation of DNA replication proteins |
| reactome | R-HSA-597592 | Post-translational protein modification |
| reactome | R-HSA-597592 | Post-translational protein modification |
| reactome | R-HSA-69278 | Cell Cycle, Mitotic |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD427 | ABT737 | 5 |
| iGMDRD670 | ML 210 | 3 |
| iGMDRD779 | PRL-3 Inhibitor I | 1 |
| iGMDRD781 | Sirolimus | 3 |
| iGMDRD151 | CHM-1 | 4 |
| iGMDRD433 | Lexibulin | 3 |
| iGMDRD387 | CHIR-99021 | 2 |
| iGMDRD889 | Compound 7d-cis | 4 |
| iGMDRD420 | Leucascandrolide A | 6 |
| iGMDRD1008 | SR-II-138A | 2 |
| iGMDRD466 | Chaetocin | 3 |
| iGMDRD280 | CYTOCHALASIN B | 6 |
| iGMDRD634 | SCHEMBL2608041 | 1 |
| iGMDRD446 | LY 2183240 | 4 |
| iGMDRD639 | YK 4-279 | 3 |
| iGMDRD66 | Doxorubicin | 1 |
| iGMDRD61 | Kinetin riboside | 2 |
| iGMDRD193 | Fqi1 | 5 |
| iGMDRD782 | DC-45-A2 | 1 |
| iGMDRD885 | Compound 110 | 3 |
| iGMDRD870 | BRD63610 | 2 |
| iGMDRD138 | PX 12 | 3 |
| iGMDRD260 | FQI-2 | 3 |
| iGMDRD255 | SB225002 | 2 |
| iGMDRD64 | Parbendazole | 7 |
| iGMDRD60 | Quinoclamine | 2 |
| iGMDRD23 | Gossypol | 4 |
| iGMDRD356 | PNU-74654 | 3 |
| iGMDRD451 | Serdemetan | 2 |
| iGMDRD188 | Piperlongumine | 5 |
| iGMDRD399 | Selumetinib | 3 |
| iGMDRD506 | Fedratinib | 4 |
| iGMDRD562 | Navitoclax | 6 |
| iGMDRD560 | MK-2206 | 2 |
| iGMDRD345 | Compound 10b [PMID: 11504634] | 2 |
| iGMDRD79 | Gemcitabine | 4 |
| iGMDRD486 | Tosedostat | 1 |
| iGMDRD584 | VER 155008 | 1 |
| iGMDRD512 | nutlin 3 | 5 |
| iGMDRD211 | (1S,3R)-RSL3 | 2 |
| iGMDRD123 | Isoevodiamine | 3 |
| iGMDRD435 | BI-2536 | 8 |
| iGMDRD811 | Anthracycline | 2 |
| iGMDRD57 | Chloropentafluorobenzene | 4 |
| iGMDRD351 | GW843682X | 1 |
| iGMDRD237 | ABT-751 | 4 |
| iGMDRD434 | BMS-536924 | 5 |
| iGMDRD137 | Indisulam | 3 |
| iGMDRD505 | Pevonedistat | 4 |
| iGMDRD300 | Tozasertib | 3 |
| iGMDRD886 | Compound 1541A | 2 |
| iGMDRD552 | AZD-1775 | 2 |
| iGMDRD286 | Nsc 632839 | 13 |
| iGMDRD414 | MST-312 | 2 |
| iGMDRD329 | Merck60 | 7 |
| iGMDRD366 | PI-103 | 8 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in TOP2A
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.